Baseline levels of dynamic CD4⁺ T cell adhesion to MAdCAM-1 correlate with clinical response to vedolizumab treatment in ulcerative colitis: a cohort study

Clarissa Allner, Michaela Melde, Emily Becker, Friederike Fuchs, Laura Mühl, Entcho Klenske, Lisa Müller, Nadine Morgenstern, Konstantin Fietkau, Simon Hirschmann, Raja Atreya, Imke Atreya, Markus F. Neurath and Sebastian Zundler *

Abstract

Background: While the number of therapeutic options for treating inflammatory bowel diseases (IBD) is increasing, evidence for rational treatment decisions is scarce in many cases. In particular, appropriate biomarkers to predict the response to the anti-α4β7 integrin antibody vedolizumab are currently lacking.

Methods: We performed a cohort study with 21 patients suffering from ulcerative colitis (UC), in which first-time treatment with vedolizumab was initiated. CD4⁺ T cells were isolated from the peripheral blood and dynamic adhesion to recombinant mucosal vascular addressin cell adhesion molecule (MAdCAM-)1 in vitro as well as the effect of vedolizumab on such adhesion in vitro was determined. The expression of α4β1 integrin on peripheral blood CD4⁺ T cells was quantified by flow cytometry. Electronic patient records were reviewed to determine clinical response to vedolizumab.

Results: Dynamic adhesion of peripheral blood CD4⁺ T cells to MAdCAM-1 and the reduction of adhesion following vedolizumab treatment in vitro were higher and the change in α4β1 expression on CD4⁺ T cells was different in vedolizumab responders and non-responders. Responders could be identified with high specificity and positive-predictive value.

Conclusions: Determining dynamic adhesion of CD4⁺ T cells to MAdCAM-1 and the in vitro response to vedolizumab before treatment initiation or dynamic integrin regulation in the early course of treatment seem to be promising tools to predict the clinical response to vedolizumab therapy. Larger prospective studies are warranted.

Keywords: Inflammatory bowel diseases, T cells, Vedolizumab, Adhesion, Gut homing
Background
Despite an increasing therapeutic armamentarium for the treatment of inflammatory bowel diseases (IBD), disease activity can still not be sufficiently controlled in a considerable number of patients [1]. Response to the available agents is observed only in portions of patients [2–4] and, additionally, patients may lose response over time [5]. Moreover, there is evidence indicating that the probability of response to a subsequent treatment is lower, if previous therapies have failed [6], and health care systems may be encumbered with costs for ineffective therapies [7].

Thus, treatment selection in individual patients remains an important challenge. Since head-to-head studies and biomarkers for the prediction of response to therapy are largely lacking, objective guidance driving such treatment decisions is low.

The anti-α4β7 antibody vedolizumab is successfully used for the treatment of IBD since 2014 [3, 8] and has been shown to inhibit immune cell homing to the inflamed gut [9, 10] indicating that cell trafficking is a central event in the pathogenesis of IBD [11]. Randomized controlled trials [3, 8], as well as several real-world cohorts [12–14], demonstrated the efficacy and safety of vedolizumab in ulcerative colitis (UC) and Crohn’s disease (CD). Vedolizumab is considered to be rather “slow-acting” [15], which might be explained by its mode of action, not directly targeting intestinal immune cells but only their replenishment by recruitment of cells from the peripheral blood [16]. Therefore, to avoid long periods of ineffective treatment in non-responders, the identification of biomarkers to predict response to vedolizumab therapy is a particularly unmet need. Moreover, since vedolizumab rather acts in the peripheral blood than in intestinal tissue, the drug might provide an especially convenient opportunity for the determination of biomarkers with low invasiveness.

We had previously introduced a dynamic adhesion assay to study the adhesion of immune cells to cell adhesion molecules [17]. In this context, we had reported the anecdotal observation that the extent of dynamic adhesion of peripheral blood CD4+ T cells from IBD patients to the α4β7 ligand mucosal vascular adhesion molecule (MAdCAM-)1 in this assay before initiation of vedolizumab treatment seemed to correlate with subsequent clinical response to therapy.

Here, we conducted a retrospective cohort study in UC patients treated with vedolizumab to further investigate this hypothesis. We show that dynamic adhesion to MAdCAM-1 is higher in responders than in non-responders and that vedolizumab treatment in vitro leads to a stronger reduction of adhesion in responders compared with non-responders. High levels of dynamic adhesion had a high specificity and positive predictive value for the response to treatment.

Methods

Patients with IBD
After informed written consent, we collected peripheral blood from adult patients with an established diagnosis of UC (n = 23) directly before the initiation of first-time vedolizumab treatment at the IBD Outpatient Department of the Medical Clinic 1 of the University Hospital Erlangen. Some patients, additional blood samples were collected after 6 weeks of treatment. The procedures were approved by the institution’s ethics committee (Ethics Committee of the Friedrich-Alexander-University Erlangen-Nuremberg). Vedolizumab therapy was conducted according to standard clinical protocols.

Table 1 summarizes the donors’ baseline characteristics.

Cell isolation and in vitro treatment
Peripheral blood mononuclear cells (PBMCs) were obtained by standard density gradient centrifugation with Lymphocyte Separation Medium (Anprotec). Subsequently, CD4+ T cells were isolated from PBMCs with immunomagnetic beads (Miltenyi Biotec) according to the manufacturer’s instructions. CD4+ T cells were fluorescently labeled with carboxyfluorescein succinimidyl ester (CFSE; Life Technologies). Labeled cells were resuspended at 1.5 million cells/mL in RPMI 1640 medium (Thermo Fisher) with 1% penicillin/streptomycin (Biochrom) and 10% FCS (Pan Biotech) and incubated with or without the anti-α4β7 integrin antibody vedolizumab (10 μg/mL, Takeda) in vitro. Finally, cells were harvested and resuspended in adhesion buffer (pH 7.4; 150 mM NaCl, 10 mM HEPES, 1 mM CaCl2, 1 mM MgCl2, 1 mM MnCl2) at a concentration of 1.5 million cells/mL for subsequent use in dynamic adhesion assays.

| Table 1 Baseline characteristics of included patients | Ulcerative Colitis |
|-------------------------------------------------------|--------------------|
| Number of patients | 21 |
| Age (mean, range) | 36.8 (19–70) |
| Female [%] | 48 |
| Smoking status [%] | |
| Never | 95 |
| Current | 5 |
| Mayo clinical score (mean, range) | 4.1 (1–7) |
| Adjunctive therapy [%] | |
| Steroids | 42.9 |
| Immunosuppressants | 14.3 |
| Previous exposure to anti-TNF [%] | 76 |
| Previous surgery [%] | 0 |
| Localization [%] | |
| E1: 19 | |
| E2: 24 | |
| E3: 57 | |
Dynamic live cell in vitro adhesion assays
Dynamic live cell adhesion was analysed as determined previously [17, 18]. In brief, the inside of miniature borosilicate capillaries (Vitrocom) was coated with Fc chimera of rhMAdCAM-1 (R&D Systems) at a concentration of 5 μg/mL in 150 mM NaCl with 10 mM HEPES for 1 h at 37 °C. Next, the coating solution was carefully removed and unspecific binding sites were blocked with 5% bovine serum albumin (BSA) in phosphate buffered saline (PBS) for another hour at 37 °C. Capillaries were connected to plastic tubing, which was inserted in an adjustable flow rate peristaltic pump (Baoding Shenchen Precision Pump Company).

Perfusion speed was set to 10 μL/min and cells prepared as mentioned above were perfused through the capillaries. Time-lapse confocal microscopy was used to quantify dynamic adhesion to MAdCAM-1 over a 3 min period. Briefly, overlay of three sequential images from the beginning and the end of the sequence in ImageJ (NIH) allowed quantification of adherent cells before and after the adhesion period. The difference was calculated to obtain dynamic adhesion during these 3 mins.

Outcomes
Electronic patient records were retrospectively reviewed to determine clinical response to vedolizumab treatment after 15 weeks (mean 14.7 weeks ± 0.2 weeks SEM) of therapy. The Mayo Clinical Score (MCS, i.e. non-invasive 9 point-score [19]) was used to determine clinical disease activity. Two patients that had previously undergone proctocolectomy and received vedolizumab for pouchitis were excluded from the intention-to-treat analysis (Fig. 1).

Clinical response was defined as a reduction of MCS ≥ 2 or, alternatively, steroid-free remission (MCS < 2) in patients who initiated treatment in steroid-dependent clinical remission.

Flow Cytometry
For the analysis of α4β1 expression on CD4+ T cells from the peripheral blood, PBMCs were isolated, stained with antibodies against CD4 (VioBlue, VIT4; Miltenyi Biotec), α4 integrin (FITC, MZ18-24A9; Miltenyi Biotec), β1 integrin (AF647, TS2/16; Biolegend), and fixed with the FoxP3/Transcription Factor Staining Buffer Set (eBioscience). Flow cytometry was performed on LSR Fortessa (BD) and MACSQuant (Miltenyi Biotec) instruments.

The difference in α4β1 expression on CD4+ T cells between week 0 and week 6 was calculated. Amending the data available from a previously published cohort [20], α4β1 expression differences in responders and non-responders were analysed.

In a separate analysis, we stained PBMCs with antibodies against CD4, α4 integrin and β7 integrin (PerCP-Cy5.5, FIB27; Biolegend). Additionally, vedolizumab was labeled with AF647 (AF647 labeling kit; ThermoFisher) and used to stain these PBMCs at a concentration of 10 μg/mL. The rate of vedolizumab+ cells was determined after gating on CD4+α4+β7+ cells.

![Fig. 1 Patient inclusion chart and clinical response](image)
Statistics
Graph Pad Prims (Graph Pad Software) was used to perform statistical comparisons. Adhesion and expression levels were compared with Mann-Whitney test. Bar charts display mean values with SEM. Cut-offs were determined by receiver operator characteristics (ROC) analysis. Significance levels are indicated by asterisks (* \( p < 0.05 \), ** \( p < 0.01 \), *** \( p < 0.001 \)).

Results
Higher dynamic adhesion of CD4+ T cells from UC patients to MAdCAM-1 in responders to vedolizumab therapy compared with non-responders
From the 21 vedolizumab-treated patients with UC that underwent analysis, 12 (57.1%) had a clinical response, while 9 (42.9%) were non-responders (Fig. 1).

In the dynamic adhesion assays performed in these patients, almost no adhesion to negative control capillaries was observed (Suppl. Fig. 1). Moreover, we performed flow cytometric analyses to demonstrate that the vedolizumab concentration used indeed leads to substantial binding to \( \alpha \beta 7 \) integrin-expressing CD4+ T cells (Suppl. Fig. 2).

In patients with a response, we observed high numbers of CD4+ T cells adhering to MAdCAM-1 in the dynamic adhesion assays, whereas adhesion of CD4+ T cells from patients classified as non-responders to MAdCAM-1 was substantially lower (Fig. 2a, b). Therefore, we performed a ROC analysis that revealed an area under the curve (AUC) of 0.76 (95% confidence interval (CI) 0.55–0.97; Fig. 2c). A dynamic adhesion of 8.5 cells/3 min was identified as the best cut-off value, which was associated with a specificity of 100% and a sensitivity of 50% for the identification of response to vedolizumab treatment. The positive and negative predictive values were 100 and 60%, respectively (Table 2A). Additionally, a cut-off value of 2.5 cells/3 min was able to identify non-responders with 83.3% specificity and 55.6% sensitivity. The positive and the negative predictive values were 71.4% (Table 2B).

In a separate analysis, we evaluated whether the extent of reduction of dynamic adhesion of CD4+ T cells to MAdCAM-1 following in vitro treatment with vedolizumab also correlated with the outcome of therapy. Indeed, the reduction of dynamic adhesion was more pronounced in responders compared with non-responders (Fig. 2d). In ROC analysis, the AUC was 0.80 (95% CI 0.60–0.99; Fig. 2e). Using a cut-off value of a reduction of adhesion of 8.5 cells/3 min, responders to vedolizumab treatment could be identified with 100% specificity and 50% sensitivity. Positive and negative predictive values were 100 and 60%, respectively (Table 2B). Moreover, a cut-off value of a reduction of adhesion of 2.5 cells/3 min distinguished between non-responders and responders with 83.3% specificity and 66.7% sensitivity. The positive predictive value for non-response was 75% and the negative predictive value 76.9% (Table 2D).

Together, high absolute adhesion to MAdCAM-1 seemed particularly suitable to predict response, while low reduction of adhesion was more feasible to predict non-response. Consistently, when combining both parameters, we found that 100% of those patients with an adhesion above 8.5 cells/3 min and a reduction of adhesion induced by vedolizumab treatment in vitro of more than 2.5 cells/3 min had a clinical response, whereas 75% or the patients with an adhesion below 8.5 cells/3 min and a reduction below 2.5 cells/3 min had a non-response. Among the seven patients with adhesion below 8.5 cells/3 min and reduction of adhesion above 2.5 cells/3 min, 57.1% were responders (Table 2E).

Dynamic changes in \( \alpha \beta 1 \) expression early during vedolizumab treatment correlate with response to therapy
While these data suggested that the function of \( \alpha \beta 7 \) in vitro correlates with clinical response to vedolizumab therapy, we had previously shown that other homing pathways may bypass \( \alpha \beta 7 \) blockade and may in that way modulate clinical effects of vedolizumab. In particular, we have shown that \( \alpha \beta 7 \) blockade may be bypassed by homing of \( \alpha \beta 7 - \) and \( \alpha \beta 1 - \) expressing T cells via \( \alpha \beta 1 \) in vivo [21]. Moreover, we had previously also suggested that clinical response to vedolizumab treatment at week 16 can be predicted by dynamic changes in \( \alpha \beta 1 \) expression on CD4+ T cells from week 0 to week 6 [20], which might also be in line with circumvention of \( \alpha \beta 7 \) blockade by \( \alpha \beta 1 \) as an alternative homing pathway. Therefore, we also analyzed the regulation of \( \alpha \beta 1 \) expression in several additional patients of the present cohort and now report the results of the extended cohort including a total of 26 UC patients.

In the previously reported cohort, all responders to vedolizumab treatment had decreasing \( \alpha \beta 1 \) levels on CD4+ T cells and all non-responders had increasing \( \alpha \beta 1 \) levels on CD4+ T cells. Although we now observed some exceptions from this distribution, there was still a significant and substantial difference between the development of \( \alpha \beta 1 \) expression from week 0 to week 6 (Fig. 3a, b). In the ROC analysis the AUC was 0.90 (95% CI 0.75 to 1.00; Fig. 3b). For the determination of clinical response to vedolizumab therapy, the best sensitivity of 83.3% and specificity of 87.5% was achieved by a cut-off of 0.05% expression change of \( \alpha \beta 1 \) on CD4+ T cells in week 6 compared with week 0. This was associated with a positive predictive value of 93.8% and a negative predictive value of 70.0%.

Discussion
Treatment decisions are a constant challenge in IBD. While more and more agents are available to treat UC
and CD, there is no clear sequence of preferred treatments [22] and, thus, the choice of treatment often remains an individual consideration. In some cases, the presence of complications like fistulae [23] or associated conditions like arthritis [24] may help to decide, but in most cases, not evidence-based aspects like patient preferences may be even more important. Apart from one very recent example comparing the efficacy of vedolizumab and adalimumab for achieving clinical remission at week 52 in UC [25], prospective head-to-head studies comparing biological treatments for IBD are lacking. Since it is not likely that appropriate additional randomized head-to-head

Fig. 2 Dynamic adhesion of CD4+ T cells to MAdCAM-1 in the cohort of 21 UC patients. a Representative dynamic adhesion assays from a responder (left) and a non-responder (right) to vedolizumab treatment. Overlay images from the beginning and the end of the collected time-lapse sequences with enumeration of adhering cells (white, some of them highlighted with yellow arrows) are shown. Scale bar – 50 μm. b Dynamic adhesion of CD4+ T cells to MAdCAM-1 in responders (n = 12) vs. non-responders (n = 9). Statistical comparison with two-tailed Mann-Whitney test. c Receiver-operator characteristic (ROC) analysis of the dynamic adhesion of CD4+ T cells to MAdCAM-1 in responders vs. non-responders. The p-value is indicated. d Reduction of dynamic adhesion of CD4+ T cells to MAdCAM-1 after vedolizumab treatment in vitro in responders (n = 12) vs. non-responders (n = 9). Statistical comparison with two-tailed Mann-Whitney test. e Receiver-operator characteristic (ROC) analysis of the reduction of dynamic adhesion of CD4+ T cells to MAdCAM-1 after vedolizumab treatment in vitro in responders vs. non-responders. The p-value is indicated.
studies will be performed in the near future to sufficiently guide treatment decisions in particular treatment situations, the identification of biomarkers predicting the individual response or non-response of patients to certain agents is an alternative strategy to make IBD therapy more efficient.

The feasibility of this concept has been previously demonstrated in studies showing that the quantification of target cells for the anti-TNF-α antibody adalimumab during confocal endomicroscopy and the baseline expression of αE integrin predicted subsequent response to adalimumab and the anti-β7 antibody etrolizumab, respectively [26, 27]. With regard to vedolizumab, a broad number of observations has been made: While gene expression profiling identified a considerable number of genes that were significantly differentially expressed following vedolizumab therapy, none of them was able to predict treatment outcomes [28]. However, another study reported that response to vedolizumab was associated with pre-therapeutic composition of the intestinal microbiome [29]. Moreover, we had suggested that dynamic changes in the expression of α4β1 on peripheral blood CD4+ T cells in the early course of vedolizumab treatment and the baseline dynamic adhesion of CD4+ T cells to MAdCAM-1 in vitro might predict subsequent therapeutic response [17, 20].

Here, we further investigated these hypotheses. Using a dynamic adhesion assay suitable to quantify the adhesion of CD4+ T cells to MAdCAM-1 under physiological shear stress [18], we show that in our cohort of 21 UC patients, more T cells from responders than from non-responders adhered to MAdCAM-1 prior to initiation of vedolizumab therapy. Consistently, in vitro treatment with vedolizumab reduced adhesion in responders stronger than in non-responders. AUCs determined with ROC analyses were around 0.8. This corresponds to a fair to good test accuracy [30] and is comparable with the accuracy of fecal calprotectin quantification for the prediction of endoscopic remission in UC [31]. Contingency table analyses showed that the ideal cut-off values determined in ROC analyses for the identification of responders either based on adhesion to MAdCAM-1 or on the reduction of adhesion by vedolizumab had high specificity, but only moderate sensitivity due to a number of false-negative results. However, this also mirrored in high positive predictive rates. Consistently, lower cut-off values were better suited to identify non-responders. When combining the information on adhesion to MAdCAM-1 and on the reduction of adhesion by vedolizumab, it turned out that high adhesion and high reduction were strongly associated with response to treatment, while low adhesion and low reduction were clearly associated with non-response. On the contrary, medium levels of adhesion and reduction were not conclusive in this regard.

Table 2 Contingency tables and cut-offs

|   | Response | Non-Response | Sensitivity | Specificity |
|---|----------|--------------|-------------|-------------|
| A | Dynamic adhesion > 8.5 cells/3 min | 6 | 0 | PPV: 100% |
|   | Dynamic adhesion < 8.5 cells/3 min | 6 | 9 | NPV: 60% |
|   | Sensitivity: 50% | Specificity: 100% |
| B | Dynamic adhesion < 2.5 cells/3 min | 5 | 2 | PPV: 71.4% |
|   | Dynamic adhesion > 2.5 cells/3 min | 4 | 10 | NPV: 71.4% |
|   | Sensitivity: 55.6% | Specificity: 83.3% |
| C | Reduction of adhesion > 8.5 cells/3 min | 6 | 0 | PPV: 100% |
|   | Reduction of adhesion < 8.5 cells/3 min | 6 | 9 | NPV: 60% |
|   | Sensitivity: 50% | Specificity: 100% |
| D | Reduction of adhesion < 2.5 cells/3 min | 6 | 2 | PPV: 75% |
|   | Reduction of adhesion > 2.5 cells/3 min | 3 | 10 | NPV: 76.9% |
|   | Sensitivity: 66.7% | Specificity: 83.3% |
| E | Dynamic adhesion > 8.5 cells/3 min | 6 | 0 | PPV: 100% |
|   | Reduction of adhesion > 2.5 cells/3 min | 4 | 3 |
|   | Reduction of adhesion < 8.5 cells/3 min | 2 | 6 | NPV: 75% |
|   | Reduction of adhesion < 2.5 cells/3 min | 43 | 2 | NPV: 75% |

Allner et al. BMC Gastroenterology (2020) 20:103
Page 6 of 9
αβ7 integrin expression, but rather differential intrinsic functionality of this pathways in responders vs. non-responders.

We also continued to explore the suitability of changes in α4β1 integrin expression on CD4+ T cells early during vedolizumab treatment as a marker of subsequent treatment success and report the extension of a previous cohort [20] in this study. In the expanded cohort of 26 UC patients, on average, CD4+ α4β1 integrin levels declined in patients with a clinical response at week 16 within the first 6 weeks of therapy, while it increased in non-responders. Again, specificity and positive predictive value for the assessment of clinical response were high. The mechanistic explanation for this finding might be that α4β1 has been shown to represent an alternative pathway for lymphocyte gut homing, when α4β7 is blocked [21]. Thus, the determination of α4β1 integrin expression might present a promising way to predict the response to vedolizumab as a “slow-acting” drug early in the course of treatment.

It has to be underscored that several limitations have to be taken into account, when interpreting these data.

---

**Fig. 3** Dynamic expression of α4β1 integrin on CD4+ T cells in the peripheral blood of patients with UC treated with vedolizumab. 

A. Timeline of vedolizumab treatment (T1–5) with representative flow cytometry and clinical data. Flow cytometry of integrin expression on CD4+ T-cells in the peripheral blood was performed before T1 and T3. Clinical response was determined at T5. Representative flow cytometric and clinical data from a responder to vedolizumab (upper panels) and a non-responder to vedolizumab (lower panels) are shown. 

B. Left panel: Difference in the expression of α4β1 integrin on CD4+ T cells in the peripheral blood between week 0 (T0) and week 6 (T3) of vedolizumab treatment as determined by flow cytometry (n = 26; 18 responders, 8 non-responders). Statistical comparison with two-tailed Mann-Whitney test. Right panel: Receiver-operator-characteristic (ROC) analysis for prediction of clinical response to vedolizumab treatment by changes in α4β1 expression between week 0 and week 6. Significance level (left) and p-value (right) are indicated. MCS – Mayo clinical subscore.
For one aspect, they are based on an only small cohort from one single center. Moreover, clinical parameters were determined retrospectively. Thus, our study needs to be understood as a pilot study and the data cannot easily be generalized and conclusions must be drawn carefully.

Yet, these results show the promising potential of these techniques and provide a clear rationale for subsequent prospective studies with higher sample size, which are currently under way.

**Conclusion**

Analysis of the adhesion of CD4+ T cells to MAdCAM-1 on a functional level with dynamic adhesion assays in IBD patients prior to the start of treatment appears to be a promising tool for the identification of patients, which are likely to respond to therapy with vedolizumab. Similarly, changes in α4β7 integrin expression after initiation of treatment might be an early indicator of clinical success in vedolizumab-treated patients.

Provided that these findings can be confirmed and validated in larger and prospective studies, our observations might lay the basis for the prediction of success of vedolizumab treatment with the help of peripheral blood samples.

**Supplementary information**

Supplementary information accompanies this paper at https://doi.org/10.1186/s12876-020-01253-8.

**Abbreviations**

AUC: Area under the curve; BSA: Bovine serum albumin; CD: Crohn’s disease; HBI: Harvey-Bradshaw index; IBD: Inflammatory bowel disease; MAdCAM-1: Mucosal addressin vascular cell adhesion molecule 1; NCS: Mayo Clinical Score; PBMCs: Peripheral blood mononuclear cells; rh: Recombinant human; ROC: Receiver operator characteristics; SEM: Standard error of the mean; UC: Ulcerative colitis

**Acknowledgements**

The research of RA, IA, MFN and SZ was supported by the Interdisciplinary Center for Clinical Research (IZKF) and the ELAN program of the University Erlangen-Nuremberg, the Else Kröner-Fresenius-Stiftung, the Fritz Bender-Stiftung, the Dr. Robert Pfleger Stiftung, the Litwin IBD Pioneers Initiative of the Crohn’s and Colitis Foundation of America (CCFA), the Rainin Foundation, the Ernst Jung-Stiftung for Science and Research, the German Crohn’s and Colitis Foundation (DCCV) and the German Research Foundation (DFG) through individual grants (ZU 377/3-1) and the Collaborative Research Centers TRR241, 643, 796 and 1181. The present work was performed in fulfillment of the requirements for obtaining the degree “Dr. med.” for CA.

The authors thank Julia Derdau, Monique Sławik, Julia Schuster and Dorothee Dzioni for excellent technical assistance.

**Authors’ contributions**

CA, MM, EB, FF and LM1 performed the experiments. EB, EK, LM2, NM, KF, SH, RA, IA, MFN and SZ provided clinical samples, protocols, reagents or designed experiments; CA, MM and SZ analyzed and interpreted the data; CA and SZ drafted the manuscript; all authors critically read and revised the manuscript for important intellectual content and approved the final version.

**Funding**

German Research Foundation (DFG, ZU 377/3–1), Interdisciplinary Center for Clinical Research (IZKF) of the University Erlangen-Nuremberg (J63). The funding bodies provided financial support and had no role in the design of the study, in the collection, analysis and interpretation of data or in writing the manuscript.

**Availability of data and materials**

The datasets generated and analyzed during the current study are available from the corresponding author on reasonable request.

**Ethics approval and consent to participate**

All patients gave informed written consent for the study. The procedures were approved by the institution’s ethics committee (Ethics Committee of the Friedrich-Alexander-University Erlangen-Nuremberg).

**Consent for publication**

Not applicable.

**Competing interests**

S.Z. received honoraria from Takeda and Roche. M.F.N. has served as an advisor for Pentax, Giuliani, MSD, Abbvie, Janssen, Takeda and Boehringer. M.F.N. and S.Z. received research support from Takeda, Roche and Shire.

**Received**

19 September 2019 **Accepted**

30 March 2020

**Published online**

15 April 2020

**References**

1. Neurath MF. Current and emerging therapeutic targets for IBD. Nat Rev Gastroenterol Hepatol. 2017;14:269–78.

2. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GI, Kombhuth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;363:1383–95.

3. Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel J-F, Sandborn WJ, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699–710.

4. Feagan BG, Sandborn WJ, Gasiok C, Jacobstein D, Lang Y, Friedman JR, et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2016;375:1946–60.

5. Danese S, Vutton L, Peyrin-Biroulet L. Biologic agents for IBD: practical insights. Nat Rev Gastroenterol Hepatol. 2015;12:537–43.

6. Yali H, MacIsaac D, Wong J, Sellers ZM, Wren AA, Bensen R, et al. Market share and costs of biologic therapies for inflammatory bowel disease in the USA. Alumni Pharmacol Ther. 2018;47:364–70.

7. Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel J-F, Sands BE, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369:711–21.

8. Fischer A, Zundler S, Areys R, Raith T, Voskens C, Hirschmann S, et al. Differential effects of α4β7 and GPR15 on homing of effector and regulatory T cells from patients with UC to the inflamed gut in vivo. Gut. 2016;65:1642–64.

9. Schleier L, Wiendl M, Heidbreder K, Binder M-T, Areys R, Raith T, et al. Non-classical monocyte homing to the gut via α4β7 integrin mediates macrophage-dependent intestinal wound healing. Gut. 2020;69:252–63.

10. Zundler S, Becker E, Schulze LL, Neurath MF. Immune cell trafficking and retention in inflammatory bowel disease: mechanistic insights and therapeutic advances. Gut. 2019;68:1688–700.

11. Amiot A, Grimaud J-C, Peyrin-Biroulet L, Filippa J, Paliente B, Roblin X, et al. Effectiveness and Safety of Vedolizumab Induction Therapy for Patients
With Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2016;14(11): 1593–601.

13. Baumgart DC. Bokemeyer B, Drabik a, Stallmach a, Schreiber S, Vedolizumab Germany consortium. Vedolizumab induction therapy for inflammatory bowel disease in clinical practice—a nationwide consecutive German cohort study. Aliment Pharmacol Ther. 2016;43:1090–102.

14. Kopylov U, Ron Y, Avni-Biron I, Koslowsky B, Waterman M, Daheer S, et al. Efficacy and safety of Vedolizumab for induction of remission in inflammatory bowel disease—the Israeil real-world experience. Inflamm Bowel Dis. 2017;23:404–8.

15. Sandborn WJ. The present and future of inflammatory bowel disease treatment. Gastroenterol Hepatol. 2016;12:438–41.

16. Zundler S, Becker E, Weidinger C, Siegmund B. Anti-adhesion therapies in inflammatory bowel disease—molecular and clinical aspects. Front Immunol. 2017;8. https://doi.org/10.3389/fimmu.2017.00764.

17. Binder M-T, Becker E, Wiendl M, Schleier L, Fuchs F, Leppkes M, et al. Similar inhibition of dynamic adhesion of lymphocytes from IBD patients to MAdCAM-1 by Vedolizumab and Etrolizumab-s. Inflamm Bowel Dis. 2018;24: 1237–50.

18. Becker E, Schramm S, Binder M-T, Allner C, Wiendl M, Neufert C, et al. Dynamic adhesion assay for the functional analysis of anti-adhesion therapies in inflammatory bowel disease. J Vis Exp. 2018;(139). https://doi.org/10.3791/58210.

19. Lewis JD, Chuai S, Nessel L, Lichtenstein GR, Aberra FN, Ellenberg JH. Use of the non-invasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis. 2008;14:1660–6.

20. Fuchs F, Schillinger D, Atreya R, Hirschmann S, Fischer S, Neufert C, et al. Clinical response to Vedolizumab in ulcerative colitis patients is associated with changes in integrin expression profiles. Front Immunol. 2017;8 https://doi.org/10.3389/fimmu.2017.00764.

21. Zundler S, Fischer A, Schillinger D, Binder M-T, Atreya R, Rath T, et al. The α4β1 homing pathway is essential for Ileal homing of Crohn’s disease effector T cells in vivo. Inflamm Bowel Dis. 2017;23:379–91.

22. Harbord M, Elakmir R, Bettenworth D, Karimiris K, Katsanos K, Kopylov U, et al. Third European evidence-based consensus on diagnosis and Management of Ulcerative Colitis. Part 2: current management. J Crohns Colitis. 2017;11:769–84.

23. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med. 1999;340:1398–405.

24. Van Assche G, Dignass A, Reinsch W, van der Woude CJ, Sturm A, De Vos M, et al. The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: special situations. J Crohns Colitis. 2010;4:63–101.

25. Sands BE, Peyrin-Biroulet L, Loewe V, Danese S, Colombel JF, Töröner M, et al. Vedolizumab versus Adalimumab for moderate-to-severe ulcerative colitis. N Engl J Med. 2019;381:1215–26.

26. Atreya R, Neumann H, Neufert C, Waldner MJ, Billmeier U, Zapf Y, et al. In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn’s disease. Nat Med. 2014;20:313–8.

27. Vermeire S, O’Byrne S, Keir M, Williams M, Lu TT, Mansfield JC, et al. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet. 2014;384:309–18.

28. Ananthakrishnan AN, Luo C, Yajnik V, Khalili H, Garber JJ, Stevens BW, et al. Gut Microbiome Function Predicts Response to Anti-integrin Biologic Therapy in Inflammatory Bowel Diseases. Cell Host Microbe. 2017;21:633–10.e3.

29. Ferraris VA. Commentary: should we rely on receiver operating characteristic curves? From submariines to medical tests, the answer is a definite maybe! J Thorac Cardiovasc Surg. 2019;157:2354–5.

30. Utsunomiyakumakai J, Imai S, Nakamura S, Kawaiaki N, Akasaka R, Sato K, et al. Practical fecal calprotectin cut-off value for Japanese patients with ulcerative colitis. World J Gastroenterol. 2018;24;4384–92.